CG Oncology (NASDAQ:CGON) Insider Buys $299,142.25 in Stock

CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) insider Isabel Kalofonos bought 3,751 shares of CG Oncology stock in a transaction dated Wednesday, November 18th. The stock was acquired at an average price of $79.75 per share, with a total value of $299,142.25. Following the purchase, the insider directly owned 3,751 shares of the company’s stock, valued at approximately $299,142.25. This represents a ? increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website.

CG Oncology Stock Down 3.0%

NASDAQ CGON opened at $79.47 on Friday. The company’s 50 day moving average is $68.85 and its 200-day moving average is $67.24. CG Oncology, Inc. has a 12-month low of $37.01 and a 12-month high of $93.95. The firm has a market cap of $7.10 billion, a P/E ratio of -28.79 and a beta of 0.35.

CG Oncology (NASDAQ:CGON – Get Free Report) last announced its quarterly earnings results on Friday, November 6th. The company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.19. The company had revenue of $1.60 million for the quarter, compared to analysts’ expectations of $0.55 million. CG Oncology had a negative net margin of 3,851.09% and a negative return on equity of 24.58%. Equities analysts expect that CG Oncology, Inc. will post -2.97 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Wall Street Zen raised CG Oncology from a “strong sell” rating to a “sell” rating in a report on Saturday, November 7th. Royal Bank Of Canada lowered CG Oncology from an “outperform” rating to a “sector perform” rating and boosted their price objective for the company from $80.00 to $97.00 in a research note on Tuesday. Morgan Stanley increased their price objective on CG Oncology from $102.00 to $117.00 and gave the stock an “overweight” rating in a report on Wednesday. Guggenheim raised their target price on CG Oncology from $89.00 to $120.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, JPMorgan Chase & Co. lifted their target price on CG Oncology from $96.00 to $113.00 and gave the company an “overweight” rating in a report on Tuesday. Eight equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $102.22.

Get Our Latest Analysis on CG Oncology

Key Headlines Impacting CG Oncology

Here are a few of the latest headlines about CGON:

  • Positive Sentiment: Analysts raised targets and forecasts. Guggenheim lifted its price target to $120 from $89 and kept a Buy rating. HC Wainwright raised its longer-term earnings estimates and maintains a $115 target and Buy rating. Morgan Stanley also reportedly sees potential for strong appreciation. Guggenheim analyst coverage Morgan Stanley forecast
  • Positive Sentiment: Executives bought shares. CEO Arthur Kuan and another executive reportedly purchased about $2.7 million of CGON stock after the CEO described the company’s trial results as a “defining milestone.” A separate filing showed insider Isabel Kalofonos bought 3,751 shares for about $299,000. Such purchases may signal management confidence, though they do not guarantee future performance. Report on trial results and insider purchases
  • Neutral Sentiment: Clinical and financial uncertainty remains. CG Oncology is a clinical-stage biotech, and the cited earnings projections are several years out. Trial follow-up and regulatory progress remain important to the investment case.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in shares of CG Oncology in the second quarter worth $444,509,000. Bank of America Corp DE bought a new stake in CG Oncology during the second quarter valued at $69,978,000. Jefferies Financial Group Inc. purchased a new position in CG Oncology during the second quarter worth about $54,705,000. Toronto Dominion Bank grew its position in CG Oncology by 177.7% during the third quarter. Toronto Dominion Bank now owns 798,676 shares of the company’s stock worth $56,618,000 after buying an additional 511,044 shares in the last quarter. Finally, Seven Fleet Capital Management LP increased its stake in CG Oncology by 24.5% in the 2nd quarter. Seven Fleet Capital Management LP now owns 1,886,236 shares of the company’s stock worth $134,017,000 after acquiring an additional 371,085 shares during the last quarter. 26.56% of the stock is owned by institutional investors.

About CG Oncology

(Get Free Report)

CG Oncology is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company’s research centers on therapies delivered directly into the bladder. Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-Guérin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response.

Featured Articles

Insider Buying and Selling by Quarter for CG Oncology (NASDAQ:CGON)

Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.